This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Curium Invests €32M in France
Business investment

Curium Invests €32M in France

Analysis based on 6 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This investment by Curium is expected to positively impact the pharmaceutical and healthcare sectors, particularly in nuclear medicine and oncology, by increasing the availability of advanced cancer treatments. It also signals a positive outlook for France's industrial strength and its role in the European nuclear medicine supply chain.

Pharmaceuticals Healthcare
Event Summary

Curium, a global leader in nuclear medicine, announced a strategic industrial investment of over €32 million in France — Saclay, France, at the Choose France summit. This investment will establish a new European production line for 177Lu-PSMA-I&T, a targeted radioligand therapy for patients with metastatic castration-resistant prostate cancer, and create 20 highly skilled jobs. This move strengthens Curium's production capabilities for radiopharmaceuticals and positions France at the forefront of innovative cancer treatment technology, reinforcing its role in the European nuclear medicine value chain. The investment is part of Curium's broader strategy to become a theranostic player, combining diagnostics with a growing therapeutic portfolio.

Entities Involved
oth
Curium
Curium is making a strategic investment of over €32 million to establish a new production line for radiopharmaceuticals in France — Saclay, France, strengthening its position in nuclear medicine and targeted cancer therapies.
Importance 100.0 Sentiment 70.0
cnt
France
France is the recipient of Curium's significant investment, which will boost its nuclear medicine industry, create highly skilled jobs, and reinforce its position in the European nuclear medicine value chain.
Importance 80.0 Sentiment 30.0
loc
France — Saclay
France — Saclay, France, is the historic site for Curium's investment, benefiting from the creation of a new production line and 20 highly skilled jobs, leveraging its scientific ecosystem.
Importance 60.0 Sentiment 20.0
alliance
European Union
The investment by Curium aims to supply the European market with 177Lu-PSMA-I&T, addressing the growing demand for innovative radiopharmaceutical treatments across the European Union.
Importance 50.0 Sentiment 20.0
per
Ciril Faia
Ciril Faia, Curium International's Chief Executive Officer, commented on the importance of France as a production hub for Curium and the future of nuclear medicine.
Importance 20.0 Sentiment 10.0
per
Isabelle Rouzou
Isabelle Rouzou, SVP Quality and Operations at Curium International, highlighted France's suitability for the investment due to its scientific and industrial ecosystem.
Importance 20.0 Sentiment 10.0
Relationships
France related ↔ European Union
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.